Medicamen Organ.
: MEDIORG · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Medicamen Organ.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Medicamen Organics Ltd is a pharmaceutical company engaged in the development, manufacturing, and distribution of a diverse range of dosage forms including tablets, capsules, syrups, and ointments. The company provides B2B contract and third-party manufacturing services to both domestic and international pharmaceutical firms.
Business Model
The company operates through a B2B model, leveraging third-party distribution networks and loan licensing agreements to supply generic and branded formulations to government and private institutions.
Growth Outlook
Growth is expected to be driven by the expansion of its contract manufacturing services and the continued supply of pharmaceutical formulations to institutional clients.
Key Risks
- Regulatory Compliance. The company faces risks related to stringent pharmaceutical manufacturing standards and potential changes in government health policies.
- Client Concentration. Reliance on third-party distributors and contract manufacturing agreements may expose the company to revenue volatility if key partnerships are terminated.
- Input Cost Volatility. Fluctuations in the prices of active pharmaceutical ingredients and raw materials can significantly impact profit margins.
- Competitive Pressure. The generic pharmaceutical market in India is highly fragmented and competitive, which may exert downward pressure on pricing.
Start your research today
Unlock AI insights, financials, peers and live data on Medicamen Organ. and 5,000+ companies — free.
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Medicamen Organ.MEDIORG | ₹30 Cr | — | — | — | -12.8% | — | — | -32.8% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Mar 2026
Financials
Medicamen Organ.
: MEDIORG · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Medicamen Organ.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Medicamen Organics Ltd is a pharmaceutical company engaged in the development, manufacturing, and distribution of a diverse range of dosage forms including tablets, capsules, syrups, and ointments. The company provides B2B contract and third-party manufacturing services to both domestic and international pharmaceutical firms.
Business Model
The company operates through a B2B model, leveraging third-party distribution networks and loan licensing agreements to supply generic and branded formulations to government and private institutions.
Growth Outlook
Growth is expected to be driven by the expansion of its contract manufacturing services and the continued supply of pharmaceutical formulations to institutional clients.
Key Risks
- Regulatory Compliance. The company faces risks related to stringent pharmaceutical manufacturing standards and potential changes in government health policies.
- Client Concentration. Reliance on third-party distributors and contract manufacturing agreements may expose the company to revenue volatility if key partnerships are terminated.
- Input Cost Volatility. Fluctuations in the prices of active pharmaceutical ingredients and raw materials can significantly impact profit margins.
- Competitive Pressure. The generic pharmaceutical market in India is highly fragmented and competitive, which may exert downward pressure on pricing.
Start your research today
Unlock AI insights, financials, peers and live data on Medicamen Organ. and 5,000+ companies — free.
Peers · Pharmaceuticals
As of Mar 2026